Results 31 to 40 of about 37,305 (235)

a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [PDF]

, 2016
Background Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in ...
Schlenzka, Jana, Luntz, Steffen, Weisel, Katja, Hose, Dirk, Lindemann, Hans W., Nogai, Axel, Haenel, Mathias, Goldschmidt, Hartmut, Schmidt-Hieber, Martin, Wuchter, Patrick, Baertsch, Marc-Andrea, Noppeney, Richard, Hillengass, Jens, Schmidt-Wolf, Ingo G. H., Raab, Marc S., Jauch, Anna, Merz, Maximilian, Salwender, Hans, Goerner, Martin, Mai, Elias K., Klein, Stefan, Kunz, Christina, Ho, Anthony D., Graeven, Ullrich, Hielscher, Thomas, Fenk, Roland, Scheid, Christof, Martin, Hans, Reimer, Peter   +28 more
core   +1 more source

Lenalidomide-related malar rash-like lesion in patient with 5q-syndrome

Iraqi Journal of Hematology, 2019
It has become important to be careful in terms of side effects with the increased lenalidomide use. The most commonly reported adverse events with the use of lenalidomide were hematologic toxicities and less frequently peripheral edema, infections ...
Gokhan Sargin, Irfan Yavasoglu
doaj   +1 more source

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma

, 2011
Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with ...
Adrian Alegre, Beatriz Aguado, Isabel Vicuña   +2 more
core   +1 more source

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

, 2014
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation.
Cavo M, Catalano J, Moreau P, Avet Loiseau H, Qiu L, Binder D, Dispenzieri A, Belch AR, de la Rubia J, Delforge M, Oriol A, Banos A, Dimopoulos MA, Lee JJ, Ervin Haynes A, Facon T, Bahlis N, Weisel K, Cavenagh J, Chen G, Geraldes C, Chen C, Benboubker L, Fermand JP, Hulin C, Attal M, Tiab M, Anderson K, White DJ, Knight R, Pinto A, FOA, Roberto, Ludwig H, Jacques C, Van Oostendorp J   +34 more
core   +4 more sources

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!

Case Reports in Oncology, 2012
Myelodysplastic syndrome (MDS) refers to a group of haematological, monoclonal disorders. A 50-year-old woman was diagnosed with MDS 5q deletion syndrome [del(5q)], becoming dependent on blood transfusion after long-term treatment with cytotoxic drugs ...
Hassan A. Al-Jafar, Salih Al-Azmi, J.A. Qassem, Eman A. Hasan, Arwa Alduaij   +4 more
doaj   +1 more source

The Effect of Lenalidomide Ointment on TNF-α Tissue Levels in Mice with Imiquimod-Induced Psoriasis Effect of Lenalidomide Ointment on TNF-α Tissue Levels in Mice with Imiquimod-Induced Psoriasis.

مجلة كلية الطب, 2023
Background: Lenalidomide is an immunomodulatory drug having notable anti-inflammatory, and anti-antineoplastic properties. Lenalidomide suppresses the production of pro-inflammatory cytokines that have been linked to a variety of hematologic ...
sajjad Mustafa Thamer, Mohammed Q. Yahya
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Haematologica, 2013
The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and
Meletios A. Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T. Petrucci, Philip Lewis, Annabel Nixon, Jingshan Zhang, Jay Mei, Antonio Palumbo   +9 more
doaj   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source